Search

Meeting Report: European School of Haematology International Conference of Haematological Disorders in the Elderly

The meeting started by reviewing demographic aspects, physiological changes encountered in the elderly, as well as the definition of older and elderly people, frailty and comorbidity.

Read more

Major research funding calls are out now

First, the Innovative Medicines Initiative published its final call under the EU Seventh Framework Programme. Interestingly for hematologists, the call includes a project called ‘Blood-based biomarker assays for personalized tumour therapy: value of circulating biomarkers’.

Read more

The International Society on Thrombosis and Haemostasis (ISTH) Hosts its Second Advanced Training Course on Thrombosis and Haemostasis on March 13-16, 2014

The Second Advance Training Course is a follow-up to the successful inaugural course organized in 2011 and attended by 200 professionals. Course speakers include nine international and regional experts in the field of thrombosis and haemostasis.

Read more

Research must provide ‘more good news on outcomes’ while patients need simple and effective information

On behalf of EHA, professor Giovanni Martinelli and professor Theo de Witte spoke of their cutting edge research and the next steps in personalized medicine research in hematology.

Read more

Sanquin Blood Supply will culture erythrocytes for transfusion purposes

ABO-Rh-D matched transfusions result in alloimmunisation in 3-5% of recipients. Once allo-immunized, it may become very difficult to find appropriate donor erythrocytes, especially when multiple antibodies or rare combinations of antibodies are present.

Read more

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Read more

Position of EHA on the Harmonization of Training and Education in Europe

 

The challenge
Education and training are largely national competencies.

Read more

Position of EHA on Research Funding

 

The challenge
The cost of biomedical research is great, but the cost of disease is immense. An ageing population and expensive innovations in medicine put an increasing burden on already stressed healthcare budgets.

Read more

Position of EHA on Clinical Trials

 

The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.

Read more

Position of EHA on Personalized Medicine

 

The challenge
Despite its apparent complexity, personalized medicine could transform healthcare, by tailoring healthcare solutions to the individual patient, delivering ‘the right treatment to the right patient at the right time’ – and helping to get more value from healthcare spending.…

Read more